JSR to establish the new JSR Bioscience and Informatics R & D Center in Tonomachi, Kawasaki City
Keio University, Bank of Yokohama and Kawasaki City Institute of Industrial Promotion concluded a memorandum of understanding towards industrial promotion of Kawasaki City
PeptiDream and JSR Initiate a Joint Development Program to Identify Peptides Applicable to Affinity Chromatography
AccuRna signs Feasibility Study Agreement with Astellas Innovation Management LLC
【PeptiDream Inc.】「On line article about Patrick Reid, PeptiDream representative director and president, published in Forbes.」
【NanoCarrier Co.,Ltd.】「Press release by VBL Therapeutics on “VBL Final Phase 1/2 Study Results Presented at ASCO Demonstrate VB-111 Dose Dependent Increase in Overall Survival and 58% CA-125 Response Rate in Platinum-Resistant Ovarian Cancer”」
【NanoCarrier Co.,Ltd.】「Press release by VBL Therapeutics on “Radiographic Analysis of VB-111 Phase 2 and 3 Clinical Trials in Recurrent Glioblastoma Shows Survival Benefit Associated with Objective Responses and Distinct Signature of VB-111 Activity”」
【iCONM/COINS】「COINS SDGs promotion video has been completed.」
【Braizon Therapeutics,Inc.】「Commencement of U.S.A. Operations at LabCentral in Boston, MA.」
Keio University, Keio University Hospital
Shimadzu Corporation will establish a new base for its measurement business in Kawasaki City by December 2020. The convenient location of the base near Haneda Airport is expected to accelerate open innovation.
Feature article of "In-body hospitals" which is the core theme of iCONM* / COINS was published in Nature.
GE Healthcare Japan and Daiwa House Industry Collaborate at the Tonomachi Open Innovation Base King SkyFront "District A" to provide a platform to accelerate the practical application of regenerative medicine
COINS held 35th Seminar at the LiSE, Tonomachi KING SKYFRONT
Kawasaki City signs a memorandum of mutual cooperation on life sciences for the first time as a municipality with LINK-J
Kawasaki KING SKYFRONT Tokyu REI Hotel to be opened on 1 June 2018.
Keio University sets up consultation desk for entrepreneurs at Tonomachi Wellbeing Research Campus
PeptiDream Announces Initiation of a Molecular Imaging Study in Discovery Alliance with Bristol-Myers Squibb
The KingSkyFront Networking Council is established
CYBERDYNE obtained marketing clearance from U.S. FDA for Medical HAL as a medical device.
Kawasaki City and Munich Biocluster Management Organizations (BioM) sign memorandum of understanding on promoting business exchanges centered on health, medicine, and welfare.
9 Doctors in Southeast Acquired Minimally Invasive Surgery. Doctors learned VATS and Small-Thoractomy Techniques at Johnson & Johnson.
Medtronic Innovation Center Japan to be opened at Kawasaki KINGSKYFRONT on 1 September 2017
Tokyo Institute of Technology and Kawasaki City are Combining Forces in R&D on Computational Drug Discovery for Middle Molecules at Kawasaki KING SKYFRONT
Notice of Orphan Drug Designation of NC-6004 (biliary tract cancer) by the U.S. FDA
CYBERDYNE won the Prime Minister’s Award in the third Nippon Venture Awards
Kazunori Kataoka is elected a foreign member of the National Academy of Engineering (USA), “For pioneering contributions to the design of supramolecular nanostructures and their application to drug and gene delivery systems.”
Kawasaki's life science research district sale completed: JSR Corporation and Kawasumi Laboratories Inc., succeed in winning the bid
KINGSKYFRONT region is selected as Wellbeing Research Campus
Ceremony to commemorate the completion of the Create Medic Research and Development Center
Under the supervision of medical professionals, the manual for proper usage of HAL® for Medical Use (Lower Limb Type) has now been published ~ Commencement of the world’s first insured robotic treatment covered under general public health insurance ~
"PeptiDream Announces Start of Preclinical Testing of Anti-Influenza Candidate PD-001"
NanoCarrier Co., Ltd. announces start of phase one clinical trials in Taiwan of drug delivery product for treatment of head and neck cancer.
Application for national health insurance coverage for HAL for Medical Use (Lower Limb Type) submitted to the Ministry of Health, Labour and Welfare
KINGSKYFRONT area is selected as a ‘feasibility hub’ by the Japan Science and Technology Agency (JST)
HAL for Medical Use (Lower Limb Type) received approval to be manufactured and sold as a medical device by the Ministry of Health, Labour and Welfare
Commencement of investigator-initiated clinical trial of stroke patients using HAL® for Medical Use (Single-Leg Model) ~Step towards the medical device approval and expansion of Cybernic treatment~
Results of a Phase Ib Clinical Study of NC-6004 in the US
3rd COINS International Symposium "Towards Smart Health Society - Challenge of Kawasaki based Medical Innovation -"
KINGSKYFRONT concept images updated
Fujifilm establishes “Cellular Dynamics International Japan” to launch iPSC business for drug discovery support in Tonomachi (Kawasaki, Japan)
Next Generation Robots Introduced to Haneda Airport Domestic Passenger Terminal! ~HAL® for Labor Support (Lumbar type), Transport Robot, and Cleaning Robot Commence Operations~
Opening Ceremony of Innovation Center of NanoMedicine (iCONM)
Johnson & Johnson K.K. First Anniversary of Tokyo Science Center, a Training Center for Healthcare Professionals - The number of visitors from home and abroad exceeds 22,000 -
Novel Norovirus Strain Identified by Kawasaki City Institute for Public Health
PeptiDream Inc., announces the opening of facilities at KAWASAKI KING SKYFRONT.
Kazunori Kataoka and colleagues publish paper on ‘chemical surgery’ for cancer treatment.
Bridge across Tamagawa River to link Haneda Airport to KING SKYFRONT
Solvay opens research and innovation laboratory at LiSE, KING SKYFRONT.
Professor Kazunori Kataoka, Tokyo University and the Director, Innovation Center of NanoMedicine(iCONM) received 2015 Gutenberg Research Award.
Professor Kataoka and colleagues at the COINS（Center of Open Innovation Network for Smart Health） describe their latest findings in the following paper:
CYBERDYNE Inc. submitted final application for market clearance from the U.S. Food and Drug Administration (“FDA”) ~ the first DeNovo submission by a Japanese company for a “novel” medical device
HAL received the world-first certificates of an international safety standard as wearable robots for workers and caregivers
Herbert Lauterbach Award 2014 to Bergmannsheil Bochum for HAL- exoskeleton research
Fujifilm enters the PET (positron emission tomography) radiopharmaceutical market
Central Institute for Experimental Animals featured in Nature article
CYBERDYNE Inc. launched HAL® for Task Support to enter fields of heavy work assistance devices
Article regarding efficacy of HAL For Medical Use was published in US medical magazine “Neurology”
FUJIFILM RI Pharma Co., Ltd. and CYBERDYNE Inc announce that they will open facilities at KAWASAKI KING SKYFRONT.
Johnson & Johnson Opens Tokyo Science Center
Daiwa House Signs Land Transfer Agreement with Urban Renaissance Agency and Memorandum with Kawasaki Municipal Government
Professor Kazunori Kataoka of the University of Tokyo and Center of Open Innovation Network for Smart Health (COINS) is selected by Thompson Reuters as a ‘highly cited researcher for 2014’.
Comprehensive Agreement signed by Kawasaki Municipal Government and CYBERDYNE
Keio Team to Start World’s First Clinical Trail of New Spinal Injury Treatment
Central Institute for Experimental Animals Signed Memorandum of Understanding with United Graduate School of Veterinary Sciences, Gifu University
Toshiba Ltd and Kawasaki City develop a rapid and efficient DNA chip technology for simultaneously testing 14 major types of food borne pathogens in less than 90 minutes.
Launch of the Innovation Center of NanoMedicine (iCONM) led by Professor Kazunori Kataoka, at KING SKYFRONT.
Mariko Tosu, Ph.D. President & CEOBraizon Therapeutics. Inc.
Vol.17, November 2019
Katsuhito Asai Gene Therapy Research Institution Co.,LtdCEO
Vol.16, September 2019
Satoshi Morimoto Managing Executive Officer, Member of the Board Division Manager,Regenerative Medicine Division Head,Tonomachi CPCLife Science Institute, Inc.
Vol.15, April 2019
Haruhiro Okuda, Ph.D. Director GeneralNational Institute of Health Sciences
Vol.14, February 2019
Yutaka Akiyama Professor, Department of Computer ScienceHead, Middle Molecule IT-based Drug Discovery Laboratory (MIDL)Tokyo Institute of Technology
Vol.13, September 2018
Manabu Seo ManagerBiomedical Research DepartmentHealthcare Research & Development CenterRicoh Institute of Future TechnologyResearch and Development DivisionRICOH COMPANY, LTD.
Vol.12, May 2018
Mitsuyo Oka Senior DirectorIntegration Management OfficeMedtronic Innovation CenterMedtronic Japan Co., Ltd.
Vol.11, January 2018
Yoko Yamaguchi, Ph.D CEO & President, Director of R&DNANOEGG Research Laboratories, Inc.Visiting ProfessorSt. Marianna University School of Medicine
Vol.10, September 2017
Erika Sasaki Ph.D. DirectorCentral Institute for Experimental AnimalsDepartment of Applied Developmental BiologyProject ProfessorAdvanced Research Center, Keio University
Vol.9, March 2017
Hirofumi Shiono Section Manager1st Development Section1st Development DepartmentMedical Business Development Division NIKON CORPORATION
Vol.8, December 2016
Toru Takebayashi, MD. PhD(medicine). MPH. Dean, Graduate School of Health Management Professor, School of Medicine Department of Preventive Medicine & Public Health Keio University
Vol.7, July 2016
Keiichi Masuya, Ph.D. Vice President : Head Of Chemistry PeptiDream Inc.
Vol.6, February 2016
Mamoru Takase Senior Manager Medical Professional Education Johnson & Johnson K.K. Medical Company
Vol.5, October 2015
Nobuhiko Okabe, M.D., Ph.D. Director General Kawasaki City Institute for Public Health
Vol.4, Jun 2015
Kazunori Kataoka, Ph.D. Professor, Department of Materials Engineering, Graduate School of Engineering, and Center for Disease Biology and Integrative Medicine, Graduate School of Medicine The University of Tokyo
Vol.3, March 2015
Ryuta Nomura Chairman of the board, Chief Executive Officer Central Institute for Experimental Animals (CIEA)
Vol.2, December 2014
Jun-ichi Hata, M.D., Ph.D. Research Director, Board MemberCentral Institute for Experimental Animals (CIEA)
Vol.2, December 2014
Hideyuki Okano, M.D., Ph.D. Professor, Department of Physiology, Keio University School of Medicine, Tokyo.
Vol.1, August 2014